TACROLIMUS EXTENDED-RELEASE CAPSULES

127607 reported adverse events

These side effects are most commonly reported by patients taking TACROLIMUS EXTENDED-RELEASE CAPSULES:

# Side effect Count
0 OFF LABEL USE 13196
1 DRUG INEFFECTIVE 9055
2 PRODUCT USE IN UNAPPROVED INDICATION 6165
3 DRUG INTERACTION 5630
4 ACUTE KIDNEY INJURY 5530
5 DIARRHOEA 4599
6 TRANSPLANT REJECTION 4151
7 CYTOMEGALOVIRUS INFECTION 4081
8 PYREXIA 3881
9 COVID-19 3756
See all common reactions for TACROLIMUS EXTENDED-RELEASE CAPSULES

TACROLIMUS EXTENDED-RELEASE CAPSULES is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 MALACOPLAKIA 397 0.8668
1 SMOOTH MUSCLE CELL NEOPLASM 334 0.7990
2 TRICHODYSPLASIA SPINULOSA 303 0.7953
3 PHAEOHYPHOMYCOSIS 372 0.7766
4 POLYOMAVIRUS-ASSOCIATED NEPHROPATHY 1736 0.7403
5 DELAYED GRAFT FUNCTION 486 0.6835
6 POLYOMAVIRUS VIRAEMIA 716 0.6742
7 CHRONIC ALLOGRAFT NEPHROPATHY 465 0.5939
8 PARVOVIRUS B19 INFECTION 530 0.5922
9 POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER 2975 0.5839
See all enriched reactions for TACROLIMUS EXTENDED-RELEASE CAPSULES